Regulatory News
Position ：
- Vebreltinib Enteric Capsules approved with conditions for marketing by China NMPA2023-12-22
- Xianglei Tangzu Cream approved with conditions for marketing by China NMPA2023-12-22
- Major progress in drug review and evaluation in 20222023-11-15
- Aponermin for Injection approved for marketing by China NMPA2023-11-14
- Glofitamab Injection approved with conditions for marketing by China NMPA2023-11-14
- NMPA becomes the applicant for PIC/S2023-11-09
- Tongluo Mingmu Capsules approved for marketing by China NMPA2023-10-31
- Deucravacitinib Tablets approved for marketing by China NMPA2023-10-24
- 3rd China Biologics CMC Conference held in Hangzhou2023-10-16
- Narlumosbart Injection approved with conditions for marketing by China NMPA2023-10-10